Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro

Sergei Lobov; David R. Croucher; Darren N. Saunders; Marie Ranson

doi:10.1160/TH08-02-0119

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 100(02): 319-329
DOI: 10.1160/TH08-02-0119

Cellular Proteolysis and Oncology

Schattauer GmbH

Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro

Potential receptor interactions

Sergei Lobov

¹School of Biological Sciences, University of Wollongong, New South Wales, Australia

,

David R. Croucher^*

¹School of Biological Sciences, University of Wollongong, New South Wales, Australia

,

Darren N. Saunders

²Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia

³Department of Pathology and Laboratory Medicine, University of British Columbia and Department Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada

,

Marie Ranson

¹School of Biological Sciences, University of Wollongong, New South Wales, Australia

› Author Affiliations

Abstract

Summary

Regulation of cellular plasminogen activation is necessary for maintenance of tissue homeostasis. Despite increasing evidence for co-expression of tissue type plasminogen activator (tPA) and plasminogen activator inhibitor type-2 (PAI-2;SERPINB2) under patho/physiological conditions, the inhibition of cell-bound tPAmediated plasminogen activation by PAI-2 has not been addressed. Here we show that PAI-2 can inhibit cell-bound tPA activity in vitro and thus prevent plasmin formation. We also examined the potential involvement in this inhibition of the annexin II heterotetramer (AIIt), one of the many well characterized cell-surface co/receptors for tPA and plasminogen that efficiently promotes plasminogen activation. This receptor was of interest because AIIt has also been shown to directly bind PAI-2. Characterization of these potential interactions using purified protein systems revealed that PAI-2 directly bound AIIt via the p11 (S100A10) subunit. However, PAI-2 prevented AIIt/tPA-mediated plasminogen activation by its classic serpin inhibitory activity rather than through competition with tPA/plasminogen for binding. Further analysis showed that PAI-2 inhibited cell bound tPA-induced plasmin activity in both an AIIt-dependent and -independent manner. These data open new possibilities for further investigations regarding the regulation of cellular plasmin generation in vivo, especially in tissues where PAI-2 and tPA may be co-expressed.

Keywords

SERPINB2/PAI-2 - tPA - plasmin - annexin II heterotetramer - cell surface

Full Text

References

References
1 Thorsen S, Philips M, Selmer J. et al. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. Eur J Biochem 1988; 175: 33-39.
2 Kruithof EK, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86: 4007-4024.
3 Jankova L, Harrop SJ, Saunders DN. et al. Crystal structure of the complex of plasminogen activator inhibitor 2 with a peptide mimicking the reactive center loop. J Biol Chem 2001; 276: 43374-43382.
4 Saunders DN, Jankova L, Harrop SJ. et al. Interaction between the P14 residue and strand 2 of beta-sheet B is critical for reactive center loop insertion in plasminogen activator inhibitor-2. J Biol Chem 2001; 276: 43383-43389.
5 Lobov S, Wilczynska M, Bergstrom F. et al. Structural bases of the redox-dependent conformational switch in the serpin PAI-2. J Mol Biol 2004; 344: 1359-1368.
6 Jensen PH, Jensen TG, Laug WE. et al. The exon 3 encoded sequence of the intracellular serine proteinase inhibitor plasminogen activator inhibitor 2 is a protein binding domain. J Biol Chem 1996; 271: 26892-26899.
7 Leung KC, Byatt JA, Stephens RW. The resistance of fibrin-stimulated tissue plasminogen activator to inactivation by a class PAI-2 inhibitor (minactivin). Thromb Res 1987; 46: 755-766.
8 De Taeye B, Gils A, Declerck PJ. The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant?. Thromb Haemost 2004; 92: 898-924.
9 Huber K. Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis 2001; 11: 183-193.
10 Astedt B, Lindoff C, Lecander I. Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy. Semin Thromb Hemost 1998; 24: 431-435.
11 Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004; (Special issue – State-of-the-Art 11th International Congress on Antiphospholipid Antibodies 2004) 114: 409-414.
12 Zini JM, Murray SC, Graham CH. et al. Characterization of urokinase receptor expression by human placental trophoblasts. Blood 1992; 79: 2917-2929.
13 Hu ZY, Liu YX, Liu K. et al. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta. J Anat 1999; 194: 183-195.
14 Medcalf RL, Stasinopoulos SJ. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. Febs J 2005; 272: 4858-4867.
15 Swartz JM, Bystrom J, Dyer KD. et al. Plasminogen activator inhibitor-2 (PAI-2) in eosinophilic leukocytes. J Leukoc Biol 2004; 76: 812-819.
16 Kinnby B. The plasminogen activating system in periodontal health and disease. Biol Chem 2002; 383: 85-92.
17 Melchor JP, Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 2005; 93: 655-660.
18 Virtanen OJ, Siren V, Multanen J. et al. Plasminogen activators and their inhibitors in human saliva and salivary gland tissue. Eur J Oral Sci 2006; 114: 22-26.
19 Brown JM, Watanabe K, Cohen RL. et al. Molecular characterization of plasminogen activators in human gingival crevicular fluid. Arch Oral Biol 1995; 40: 839-845.
20 Felez J, Chanquia C, Levin E. et al. Binding of tissue plasminogen activator to human monocytes and monocytoid cells. Blood 1991; 78: 2318-2327.
21 Felez J, Miles LA, Fabregas P. et al. Characterization of cellular binding sites and interactive regions within reactants required for enhancement of plasminogen activation by tPA on the surface of leukocytic cells. Thromb Haemost 1996; 76: 577-584.
22 Kwon M, MacLeod TJ, Zhang Y. et al. S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. Front Biosci 2005; 10: 300-325.
23 Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen tissue plasminogen activator (t-PA). 2. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994; 269: 21198-21203.
24 Stillfried GE, Saunders DN, Ranson M. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res 2007; 09: R14.
25 Ranson M, Andronicos NM, O’Mullane MJ. et al. Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins. Br J Cancer 1998; 77: 1586-1597.
26 Wilczynska M, Lobov S, Ny T. The spontaneous polymerization of plasminogen activator inhibitor type-2 and Z-antitrypsin are due to different molecular aberrations. FEBS Lett 2003; 537: 11-16.
27 Croucher D, Saunders DN, Ranson M. The Urokinase/PAI-2 Complex: A new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein. J Biol Chem 2006; 281: 10206-10213.
28 Al-Ejeh F, Croucher D, Ranson M. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines. Exp Cell Res 2004; 297: 259-271.
29 Andronicos NM, Ranson M. The topology of plasminogen binding and activation on the surface of human breast cancer cells. Br J Cancer 2001; 85: 909-916.
30 Aguilar S, Corominas JM, Malats N. et al. Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression. Am J Pathol 2004; 165: 1129-1139.
31 MacLeod TJ, Kwon M, Filipenko NR. et al. Phospholipid-associated Annexin A2-S100A10 Heterotetramer and Its Subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J Biol Chem 2003; 278: 25577-25584.
32 Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005; 06: 449-461.
33 Lind SE, Smith CJ. Actin accelerates plasmin generation by tissue plasminogen activator. J Biol Chem 1991; 266: 17673-17678.
34 Parkkinen J, Rauvala H. Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. J Biol Chem 1991; 266: 16730-16735.
35 Tiberio A, Farina AR, Tacconelli A. et al. Retinoic acid-enhanced invasion through reconstituted basement membrane by human SK-N-SH neuroblastoma cells involves membrane-associated tissue-type plasminogen activator. Int J Cancer 1997; 73: 740-748.
36 Razzaq TM, Bass R, Vines DJ. et al. Functional regulation of tissue plasminogen activator on the surface of vascular smooth muscle cells by the type-II transmembrane protein p63 (CKAP4). J Biol Chem 2003; 278: 42679-42685.
37 Miles LA, Dahlberg CM, Plescia J. et al. Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 1991; 30: 1682-1691.
38 Andronicos NM, Ranson M, Bognacki J. et al. The human ENO1 gene product (recombinant human alpha-enolase) displays characteristics required for a plasminogen binding protein. Biochim Biophys Acta 1997; 1337: 27-39.
39 Kralovich KR, Li L, Hembrough TA. et al. Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18. J Protein Chem 1998; 17: 845-854.
40 Hembrough TA, Li L, Gonias SL. Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J Biol Chem 1996; 271: 25684-25691.
41 Vaughan DE, Mendelsohn ME, Declerck PJ. et al. Characterization of the binding of human tissue-type plasminogen activator to platelets. J Biol Chem 1989; 264: 15869-15874.
42 Laug WE, Cao XR, Yu YB. et al. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 1993; 53: 6051-6057.
43 Laug WE, Wang K, Mundi R. et al. Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptor in HT1080 sarcoma cells. Int J Cancer 1992; 52: 298-304.
44 Zobiack N, Rescher U, Ludwig C. et al. The annexin 2/S100A10 complex controls the distribution of transferrin receptor-containing recycling endosomes. Mol Biol Cell 2003; 14: 4896-4908.
45 Yin X, Bunn CL, Bartold PM. Detection of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 2(PAI-2) in gingival crevicular fluid from healthy, gingivitis and periodontitis patients. J Clin Periodont 2000; 27: 149-156.
46 Siao CJ, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 2002; 22: 3352-3358.
47 Svenningsson P, Greengard P. p11 (S100A10)--an inducible adaptor protein that modulates neuronal functions. Curr Opin Pharmacol 2007; 07: 27-32.
48 Yepes M, Lawrence DA. Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous system. Thromb Haemost 2004; 91: 457-464.
49 Dietzmann K, von Bossanyi P, Krause D. et al. Expression of the plasminogen activator system and the inhibitors PAI-1 and PAI-2 in posttraumatic lesions of the CNS and brain injuries following dramatic circulatory arrests: an immunohistochemical study. Pathol Res Pract 2000; 196: 15-21.
50 Akiyama H, Ikeda K, Kondo H. et al. Microglia express the type 2 plasminogen activator inhibitor in the brain of control subjects and patients with Alzheimer’s disease. Neurosci Lett 1993; 164: 233-235.